• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Bioinformatics Modernization Plan

Description: Support bioinformatics modernization plan including computational modeling, bioinformatics infrastructure development, participation in budgeting planning, etc. This effort will help to address the findings from the 2007 FDA Science Board Report where it stated that the FDA cannot fulfill its mission because its IT infrastructure is inadequate and it lacks the information science capability and infrastructure to fulfill its regulatory mandate and to regulate products based on new science. This is an agency-wide effort from all the Centers at the FDA.

Definition: Developing a modern bioinformatics infrastructure for efficient electronic regulatory processes and incorporating new technologies, scientific methodologies, and global business activities is a major FDA initiative anticipated to span the next decade. NCTR will be a significant contributor to this plan.

Public Health Outcome: The Bioinformatics Modernization Plan seeks to create new, efficient mathematical and computational techniques for analyzing massive amounts of increasingly complex data. The plan addresses current needs and anticipates future regulatory science needs. Earlier detection of adverse events due to drugs and tailoring medicine to individuals are examples.

Accomplishment: For the Bioinformatics Modernization Plan, NCTR bioinformatics staff actively participated in design of an FDA informatics governance structure that complies with statutes, providing guidance for the CPIC processes including Select (i.e., prioritization and funding), Control (i.e., review) and Evaluate (i.e., lessons learned). The NCTR Information Technology Investment Review Board was realigned with the Agency governance structure and has been functioning accordingly for the past year in evaluating and monitoring the NCTR IT investment portfolio. NCTR bioinformatics staff notably contributed to strategic planning for scientific computing infrastructure and operations, including high performance computing and scientific enclave collaborative environments. NCTR collaborated with other Centers to develop data structures, computational methods and applications appropriate for the regulatory science desktop in analyzing animal data, pharmacogenomics, and pharmacogenetics data; the adequacy of the Janus data schema to handle these data types was assessed.

Milestone DescriptionMilestone DateMilestone StatusMilestone Completion Date

1. Implement improved FDA IT governance structure


Completed 5/31/2010

2. Realign NCTR Information Technology Review Board


Completed 6/11/2010

3. Complete loading of animal toxicology data for Janus use cases


Completed 6/30/2010

4. Complete loading of pharamacogenomics data for Janus use cases


Completed 6/30/2010

5. Write a gap analysis and white paper on adequacy of Janus for animal toxicology


Completed 3/31/2011

6. Write a gap analysis and white paper on adequacy of Janus for pharmacogenomics data


Completed 3/31/2011

Key Projects Legend

Milestone StatusDefinition
Not Yet StartedWork for specific milestone has not yet been started.
CompletedMilestone and/or overall project is completed.
On TrackMilestone - On track for completion by milestone deadline. Quarter status - Project is on track for completion based on overall milestone status.
On HoldMilestone - On hold, but deadline for completion has not passed. Quarter status - Project is on hold, based on overall milestone status.
DelayedMilestone - Delayed as it has not been completed and deadline has passed. Quarter status - Project is delayed based on overall milestone status.



Information Technology


Capital Planning Investment Control CPIC

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.